Document is current
Any future updates will be listed below
-
Authors
Yuen, Kevin C. J. https://orcid.org/0000-0002-8169-2728
Vila, Greisa
Bernabeu, Ignacio
Buchfelder, Michael
Freda, Pamela
Henocque, Robin
Torre, Daria La
Maffei, Pietro
Strasburger, Christian J.
Neggers, Sebastian
Brue, Thierry
- License Information
-
More Information
Article History
Received: 12 November 2025
Accepted: 29 March 2026
First Online: 15 April 2026
Declarations
:
: Ethics approval was obtained for all participating centers, and all patients provided written informed consent before enrollment into the study.
: Kevin C. J. Yuen is the principal investigator with research support to the Barrow Neurological Institute from Ascendis, Corcept, Chiesi, and Sparrow, has served as an occasional advisory board member for Novo Nordisk, Ascendis, Chiesi, Recordati, Crinetics, Xeris, and Neurocrine, and has served as an occasional speaker for Recordati, Neurocrine and Novo Nordisk. Greisa Vila has served as a clinical trial investigator (research support to Medical University of Vienna) for Takeda, Pfizer, Ipsen, Recordati, and Corcept, and has received occasional scientific con-sultant and/or speaker fees from Pfizer, Takeda, Ipsen, Merck, Novo Nordisk, Recordati, and Lundbeck. Ignacio Bernabeu has received research grants from Pfizer and consultancy or speaker honoraria from Ipsen, Recordati, and Novo Nordisk. Michael Buchfelder has received a research grant and speaker honoraria from Pfizer. Pamela Freda has been a research investiga-tor with and received research grants from Pfizer. Robin Henocque and Daria La Torre are Pfizer employees and stock owners. Pietro Maffei is a principal investigator with research support to Padua University for clinical research studies with Pfizer, Camurus, and Recordati, and serves as an occasional scientific consultant for Pfizer and Recordati. Christian J. Strasburger received occasional consultancy or speaker honoraria from Novo Nordisk, Pfizer, Recordati, Sandoz-Hexal, Crinetics, Amolyth, Debiopharm, and Consilient Health. Sebastian Neggers has received research grants from Pfizer, and is a scientific consultant for Recordati, Novo Nordisk, Crinetics, and Ipsen. Thierry Brue has served as a clinical trial investigator for Xeris, Crinetics, Debiopharm, and Recordati, as an advisory board member for Pfizer, Recordati, and Novo Nordisk, and has received speaker fees from Pfizer, Recordati, and Novo Nordisk, and research grants from Pfizer and AFM (Association Française contre les Myopathies).
